66
Participants
Start Date
July 31, 2014
Primary Completion Date
December 31, 2017
Study Completion Date
April 30, 2018
Viagenpumatucel-L
Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
Metronomic Cyclophosphamide
One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)
"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:~* Vinorelbine~* Erlotinib~* Gemcitabine~* Paclitaxel~* Docetaxel~* Pemetrexed"
SUNY Syracuse, Syracuse
University of Pennsylvania, Philadelphia
University of Maryland Greenebaum Cancer Center, Baltimore
Georgia Regents University, Augusta
Gabrail Cancer Center, Canton
Aurora Research Institute, Green Bay
Washington University School of Medicine, St Louis
Highlands Oncology Group, Rogers
Mary Crowley Cancer Center, Dallas
Texas Oncology PA Texas Cancer Center, Abilene
University of California at Los Angeles, Los Angeles
University of California San Diego, La Jolla
University of California Davis, Sacramento
Providence Portland Medical Center- Providence Lung Cancer Clinic, Portland
Cancer Care Northwest, Spokane
University of Massachusetts, Worcester
Lead Sponsor
Heat Biologics
INDUSTRY